BeyondSpring to Participate in Upcoming Evercore ISI 2020 Conference

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on developing innovative immuno-oncology cancer therapies to transform the lives of patients with unmet medical needs, today announced that management will provide a corporate overview at the 2020 Evercore ISI HealthCONx Conference on December 2, 2020.

Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer of BeyondSpring will participate in a fireside chat session beginning at approximately 9:15 am ET.

A live webcast and replay of the webcast will be accessible on BeyondSpring’s website at www.beyondspringpharma.com under “Events & Presentation” in the Investors section.

About BeyondSpring

BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring’s lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City.

Investor Contact:

Ashley Robinson
LifeSci Advisors
[email protected]
617-430-7577

Media Contact:

Darren Opland, Ph.D.
LifeSci Communications
[email protected]
646-627-8387



Tarsius Pharma to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

TEL-AVIV, Israel, Nov. 23, 2020 (GLOBE NEWSWIRE) — Tarsius Pharma, a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat patients with blinding ocular diseases, is pleased to announce that management will participate in the Piper Sandler 32nd Annual Healthcare Conference, being held virtually on November 30th to December 3rd, 2020. In advance of the virtual conference and investor meetings, a pre-recorded corporate update given by Dr. Daphne Haim-Langford, CEO and founder of Tarsius Pharma, will be made available, on Monday, November 23rd, in the News & Events section of the company’s website. Replay of the webcast will be available for 90 days following the event. 

“We are excited to actively contribute to this prestigious conference and are looking forward to network and exchange with peers and stakeholders,” said Dr. Haim-Langford. Tarsius will be participating in 1X1 meetings between November 30th and December 3rd, additional meetings may be requested exclusively via Piper Sandler.

About Tarsius Pharma

Tarsius Pharma was established in 2016 and is focused on developing TRS, a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases.

The company has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 879598.  

Investor Contact:

Chuck Padala
LifeSci Advisors 
917-741-7792
[email protected]



Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress

Abstracts will be presented from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and OV101 (gaboxadol) clinical development program in Angelman syndrome (Phase 2 STARS study)

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that abstracts from the TAK-935/OV935 (soticlestat) clinical development program in Dravet syndrome or Lennox-Gastaut syndrome (Phase 2 ELEKTRA study) and the OV101 (gaboxadol) clinical development program in Angelman syndrome (Phase 2 STARS study), will be presented at the American Epilepsy Society (AES) 2020 Virtual Congress, taking place December 4-8, 2020.

“There remains significant unmet medical needs for the treatment of Dravet, Lennox-Gastaut, and Angelman syndromes, all of which are neurological conditions with highly impactful effects on individuals, caregivers, and their families,” said Amit Rakhit, MD, MBA, President and Chief Medical Officer at Ovid. “It is important that we continue to analyze data from studies like ELEKTRA and STARS, as we advance understanding of these conditions and work towards our goal of addressing demonstrated gaps in treatment.”

Details of the presentations are as follows:

Title: Efficacy, safety, and tolerability of soticlestat (TAK-935/OV935) as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA); Hahn, et al.
Poster Number: #851

Title: Quantitative analysis of EEG signals in STARS, a Phase 2 safety, tolerability, and exploratory efficacy study of gaboxadol in adolescents and adults with Angelman syndrome; Wang, et al.
Poster Number: #49

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines in development. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEEs). For more information on Ovid, please visit www.ovidrx.com.

About OV
935
(
soticlestat
)

Soticlestat is a potent, highly selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control. CH24H is predominantly expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol. 24HC is a positive allosteric modulator of the NMDA receptor and modulates glutamatergic signaling associated with epilepsy. Glutamate is one of the main neurotransmitters in the brain and has been shown to play a role in the initiation and spread of seizure activity. Recent literature indicates that CH24H is involved in over-activation of the glutamatergic pathway through modulation of the NMDA channel and that increased expression of CH24H can disrupt the reuptake of glutamate by astrocytes, resulting in epileptogenesis and neurotoxicity. Inhibition of CH24H by soticlestat reduces the neuronal levels of 24HC and may improve excitatory/inhibitory balance of NMDA channel activity.

Ovid and Takeda recently announced positive topline results from the randomized Phase 2 ELEKTRA study of soticlestat in children with Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS).

Takeda and Ovid are sharing in the development and commercialization costs of soticlestat on a 50/50 basis, and if successful, the companies will share in the profits on a 50/50 basis. Takeda will be responsible for commercialization in Japan and has the option to be responsible for commercialization in other countries in Asia and other selected countries. Ovid will be responsible for clinical development activities and commercialization of soticlestat in the United States, Europe, Canada and Israel. Under the terms of the agreement, Takeda received equity in Ovid and may be eligible to receive certain milestone payments based on the advancement of soticlestat.

About OV
101
(
gaboxadol
)

OV101 (gaboxadol) is a delta (δ)-selective GABAA receptor agonist in clinical development for the potential treatment of two rare neurodevelopmental conditions: Angelman syndrome and Fragile X syndrome. These receptors are thought to have a central role in tonic inhibition, a key physiological process of the brain believed to be a core pathophysiology underlying certain neurodevelopmental disorders. We believe OV101 is the first and only investigational drug to specifically target the disruption of tonic inhibition, which is believed to be a central cause of many clinical deficits in these disorders. OV101 has demonstrated in laboratory studies and animal models to selectively activate the δ-subunit of GABAA receptors and thereby modulate tonic inhibition. Positive data from the Phase 2 STARS trial of OV101 in adults and adolescents with Angelman syndrome was reported in 2018. Results of a successful Phase 2 signal-finding trial of OV101 in individuals with Fragile X syndrome (ROCKET) were reported in 2020. The Company anticipates initial data from an ongoing pivotal Phase 3 trial in Angelman syndrome (NEPTUNE) in Q4 2020. OV101 has received Rare Pediatric Disease Designation from the FDA for the treatment of Angelman syndrome and was granted Orphan Drug and Fast Track designations for Angelman syndrome and Fragile X syndrome. The European Commission (EC) has granted Orphan Drug designation to OV101 for the treatment of Angelman syndrome. The Company has licensed to Angelini Pharma the right to develop, manufacture and commercialize OV101 for the treatment of Angelman syndrome in the European Union and other countries in the European Economic Area, and also in Switzerland, Turkey, the United Kingdom and Russia.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” including, without limitation, statements regarding: clinical and regulatory development of our programs, potential benefits of OV101, OV935 and our other research programs and the anticipated reporting schedule of clinical data and the potential benefits. You can identify forward-looking statements because they contain words such as “will,” “appears,” “believes” and “expects.” Forward-looking statements are based on Ovid’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include uncertainties in the development and regulatory approval processes, and the fact that initial data from clinical trials may not be indicative, and are not guarantees, of the final results of the clinical trials and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth in Ovid’s filings with the Securities and Exchange Commission under the caption “Risk Factors”. Such risks may be amplified by the COVID-19 pandemic and its potential impact on Ovid’s business and the global economy. Ovid assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contacts

Investors and Media:

Ovid Therapeutics Inc.
Investor Relations & Public Relations
[email protected]

OR

Investors:

Argot Partners
Maeve Conneighton
212-600-1902
[email protected]

Media
:

Dan Budwick
1AB
[email protected]



iTeos to Present at Piper Sandler 32nd Annual Healthcare Conference

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 23, 2020 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that management will present at the Piper Sandler 32nd Annual Healthcare Conference, taking place December 1 – 3, 2020.

The fireside chat is now available for registered attendees to view on-demand through the duration of the event using the following link: https://pipersandler.zoom.us/rec/play/BpVKaQQBgtgH_2E-1VrjzcTFrYnR5C2p9oDagY_yXSEg1Uq7jJT7TazUadfvj3EGObsP6cX3aIuc7Y7M.VPHMhFu05uq-jZtF

A recording of the presentation is also available on the News and Events section of iTeos’ investor website at https://investors.iteostherapeutics.com/ and will remain active for 90 days.

About iTeos Therapeutics, Inc.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is being investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and encouraging preliminary single-agent activity were observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcγR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. An open-label Phase 1/2a clinical trial of EOS-448 was recently initiated in adult patients with advanced solid tumors. Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

For further information, please contact:

Investor Contact
s
:

Sarah McCabe, Zofia Mita
Stern Investor Relations, Inc.
+ 1 212 362 1200
[email protected]

Media Contact
s
:

Amber Fennell, Paul Kidwell
Consilium Strategic Communications
+44 203 709 5700
[email protected]

 



Galecto Appoints Experienced Healthcare Executive Jayson Dallas to Board of Directors

  • Has extensive experience in pharma and biotech in U.S., Europe and globally
  • Galecto completed U.S. initial public offering and plans to initiate three Phase 2 trials in the coming months

BOSTON and COPENHAGEN, Denmark, Nov. 23, 2020 (GLOBE NEWSWIRE) — Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that senior healthcare executive Jayson Dallas has joined its Board of Directors, effective November 19.

Jayson Dallas has extensive experience in both pharmaceutical and biotech industries in the U.S., Europe and globally, most recently as Chief Executive Officer of the California-based Aimmune Therapeutics, acquired by Nestlé Health Science this year. He is a member of the Board of Directors of Arena Pharmaceuticals and has previously served in senior roles for companies including Pfizer, Novartis, Roche and Ultragenyx Pharmaceuticals. His experience spans multiple therapeutic categories and covers new product launches, licensing and managing product portfolios.

Hans Schambye, CEO of Galecto, said: “I am delighted to welcome Jayson to the Galecto Board of Directors. His expertise in all aspects of the healthcare industry, from biotech to big pharma and drug development to commercialization, will be an important source of knowledge and guidance for Galecto as we continue through an exciting period of growth. Following our successful initial public offering in the U.S., we are well positioned to continue advancing our promising GB0139 product candidate and expand our clinical development pipeline with the initiation of three Phase 2 studies for other product candidates in the coming months.”

Jayson Dallas said: “It is an honor to join the Board of Directors of Galecto at such an important and dynamic moment in its history. I look forward to leveraging my industry experience to assist as Galecto advances its exciting products through clinical development and potentially to market, in order to address significant unmet medical needs.”

About Galecto

Galecto is a clinical stage biotechnology company with advanced programs in fibrosis and cancer centered on galectin-3 and LOXL2. The company’s pipeline includes an inhaled galectin-3 modulator currently in phase 2b for the potential treatment of idiopathic pulmonary fibrosis, as well as two assets about to move into phase 2 targeting myelofibrosis, NASH and oncology. The company is incorporated in the U.S. and has its operating headquarters in Copenhagen, Denmark. Further information can be found at www.galecto.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Galecto’s clinical trial plans, the significance and participation of a new board member, Galecto’s growth, and Galecto’s products and pipeline. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. For such statements, Galecto claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Galecto’s expectations. Factors that could cause actual results to differ materially from the forward-looking statements include risks and uncertainties related to the development of Galecto’s product candidates and their therapeutic potential, having adequate funds and their use, and those disclosed in Galecto’s filings with the Securities and Exchange Commission, including its Registration Statement on Form S-1. These forward-looking statements represent Galecto’s judgment as of the time of this release. Galecto disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

For more information, contact:

Galecto
Inc.
LifeSci Advisors
(media)
Hans Schambye, CEO Mary-Ann Chang
Jon Freve, CFO  
+45 70 70 52 10 +44 7483 284 853
[email protected]
[email protected]



Theratechnologies to Present at the Piper Sandler Virtual Healthcare Conference

MONTREAL, Nov. 23, 2020 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that some of its management team members will be participating in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1 and 2, 2020.

In advance of the virtual conference and investor meetings, a pre-recorded fireside chat with Paul Levesque, President and Chief Executive Officer of Theratechnologies, is now available for viewing. To access the fireside chat, please click here. The link is also posted to the ‘News’ section of the Company’s website.

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company’s website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

For media inquiries:

Denis Boucher
Vice-President, Communications and Corporate Affairs
514-336-7800

For investor inquiries:

Leah Gibson
Senior Director, Investor Relations
[email protected]
617-356-1009



CNFinance Announces Third Quarter of 2020 Unaudited Financial Results

PR Newswire

GUANGZHOU, Nov. 23, 2020 /PRNewswire/ — CNFinance Holdings Limited (NYSE: CNF) (“CNFinance” or the “Company”), a leading home equity loan service provider in China, today announced its unaudited financial results for the third quarter ended September 30, 2020.

Third Quarter 2020 Operational and Financial Highlights

  • Total loan origination volume[1] was RMB3,093.4 million (US$454.2 million) during the third quarter of 2020, compared to RMB1,708.8 million in the same period of 2019.
  • Total outstanding loan principal[2] was RMB10.4 billion (US$1.5 billion) as of September 30, 2020, compared to RMB11.3 billion as of December 31, 2019.
  • Total interest and fees income were RMB476.0 million (US$69.9 million) in the third quarter of 2020, compared to RMB678.9 million in the same period of 2019.
  • Net income was RMB50.1 million (US$7.4 million) in the third quarter of 2020, compared to RMB177.3 million in the same period of 2019.
  • Basic and diluted earnings per ADS were RMB0.73(US$0.11) and RMB0.67(US$0.10), respectively, in the third quarter of 2020, compared to RMB2.59 and RMB2.35, respectively, in the same period of 2019.

“2020 is a special year. Like many other enterprises, CNFinance has experienced significant disruptions to its operations due to the COVID-19 pandemic. We have also been adversely affected by the recent regulatory development in China’s private lending, which imposes restrictions on the maximum annual interest rates charged to borrowers.” Commented Bin Zhai, Chairman and CEO of CNFinance, “Fortunately, our resilient and dedicated team have worked closely together to overcome those challenges. We managed to improve our governance while cooperating with our trust company partners to make necessary adjustments to better align with customer needs in this special period of time. In response to the new regulation on private lending interest rates, we also worked with our funding partners to voluntarily adjust interest rates on the loans we facilitated to timely comply with the new regulation. During the third quarter of 2020, the Company witnessed recovery in major operating and financial indicators. The loan origination volume was RMB3,093.4 million, representing an increase of 81.0% over the same period last year. As the result, the Company recorded revenue of RMB476.0 million and net income of RMB50.1 million. I am pleased and proud to announce these hard-won results, given the challenges we faced in 2020.

Going forward, we will continue to leverage technology as a driving force, and the collaboration model as a solid foundation to achieve faster growth. We will also keep monitoring regulatory developments and ensure compliance with all applicable regulations to lower our risk profile, all in an effort to seize the opportunity presented by the gradually-recovering Chinese economy and to ultimately increase our shareholders’ returns.” 

Third Quarter 2020 Financial Results

Total interest and fees income decreased by 29.9% to RMB476.0 million (US$69.9 million) for the third quarter of 2020 from RMB678.9 million in the same period of 2019.

Interest and financing service fee on loans decreased by 30.1% to RMB472.5 million (US$69.4 million) for the third quarter of 2020 from RMB675.5 million in the same period of 2019, primarily due to the combined effect of (a) the decrease in the balance of average daily outstanding loan principal, which was a result of smaller loan origination volume as compared to the amount of loans repaid or collected since the third quarter of 2019, and (b) the lowered interest rate on loans facilitated in an effort to comply with recent rules and regulations issued by relevant PRC regulatory authorities, including the Decisions of the Supreme People’s Court to Amend the Provisions on Several Issues concerning the Application of Law in the Trial of Private Lending Cases issued in August 2020. 

Interest on deposits with banks increased by 2.9% to RMB3.5 million (US$0.5 million) for the third quarter of 2020 from RMB3.4 million in the same period of 2019.

Interest and fees expense decreased by 37.4% to RMB184.4 million (US$27.1 million) for the third quarter of 2020, compared to RMB294.8 million in the same period of 2019, primarily due to the decrease in the principal of the borrowings under agreements to repurchase and other borrowings.

Net interest and fees income were RMB291.6 million (US$42.8 million) for the third quarter of 2020, a decrease of 24.1% from RMB384.1 million in the same period of 2019.

Collaboration cost for sales partners increased to RMB112.5 million (US$16.5 million) for the third quarter of 2020 from RMB57.4 million in the third quarter of 2019, primarily due to the increase in outstanding loan principal under the new collaboration model as compared to the same period of 2019.

Net interest and fees income after collaboration cost was RMB179.1 million (US$26.3 million) for the third quarter of 2020, a decrease of 45.2% from RMB326.8 million in the same period of 2019.

Provision for credit losses decreased by 43.2% to RMB31.1 million (US$4.6 million) for the third quarter of 2020 from RMB54.8 million in the same period of 2019. The decrease was mainly attributable to the combined effect of (a) the decrease in outstanding principal of non-delinquent loans and loans delinquent within 90 days which resulted in a decrease in collectively assessed allowances; and (b) the increase in credit risk mitigation position put up by the sales partners which led to larger amount of guarantee asset recognized compared to the same period of 2019.

Other gains, net decreased to RMB37.4 million (US$5.5 million) for the third quarter of 2020 from gain of RMB61.8 million in the same period of 2019, primarily attributable to the decrease of net gain from the disposal of non-performing loans.

Total operating expenses increased by 4.6% to RMB117.9 million (US$17.3 million) for the third quarter of 2020, compared with RMB112.7 million in the same period of 2019.

Employee compensation and benefits decreased by 11.9% to RMB46.7 million (US$6.9 million) for the third quarter of 2020 from RMB53.0 million in the same period of 2019, primarily due to the continued decrease in the number of employees caused by the development of the new collaboration model as borrowers continue to be introduced by our sales partners.

Share-based compensation expense
 increased by 287.5% to RMB15.5 million (US$2.3 million) for the third quarter of 2020 from RMB4.0 million in the same period of 2019. According to the Company’s share option plan that was adopted on December 31 of 2019, approximately 50%, 30% and 20% of the option granted will be considered vested each of December 31 of 2020, 2021 and 2022, respectively. Related compensation cost of the option grants will be recognized over the requisite period.

Taxes and surcharges increased by 0.8% to RMB11.9 million (US$1.7 million) for the third quarter of 2020 from RMB11.8 million for the same period of 2019.

Operating lease cost decreased by 49.4% to RMB4.4 million (US$0.6 million) for the third quarter of 2020 as compared to RMB8.7 million for the same period of 2019, primarily due to continued development of the new collaboration model that allowed the Company to continue to reduce the costs associated with leased real estate previously used for sales efforts.

Other expenses increased by 11.9% to RMB39.4 million (US$5.8 million) for the third quarter of 2020 from RMB35.2 million in the same period of 2019, primarily due to the increase of advertisement fees related to the promotion of the new collaboration model.  

Income tax expense decreased by 60.3% to RMB24.6 million (US$3.6 million) for the third quarter of 2020 from RMB62.0 million in the same period of 2019, primarily due to a decrease in the amount of taxable income.

Effective tax rate increased to 33.0% for the third quarter of 2020 from 25.9% in the same period of 2019, primarily due to the fact that the share-based compensation expenses were non-deductible expenses which increased to RMB15.5 million (US$2.3 million) for the third quarter of 2020 from RMB4.0 million in the same period of 2019.

Net income decreased by 71.7% to RMB50.1 million (US$7.4 million) for the third quarter of 2020 from RMB177.3 million in the same period of 2019.

Basic and diluted earnings per ADS were RMB0.73(US$0.11) and RMB0.67(US$0.10), respectively, in the third quarter of 2020, compared to RMB2.59 and RMB2.35, respectively, in the same period of 2019. One ADS represents 20 ordinary shares.

As of September 30, 2020, the Company had RMB1.7 billion (US$0.2 billion) of cash and cash equivalents, same with RMB1.7 billion as of December 31, 2019, including RMB1.0 billion (US$0.1 billion) and RMB1.1 billion from structured funds as of September 30, 2020 and December 31, 2019, respectively, which could only be used to grant new loans and activities.

The aggregate delinquency rate for loans originated by the Company, which is calculated by dividing (i) total balance of outstanding loan principal for which any installment payment is past-due (for one or more days) as of a particular date; by (ii) the aggregate total amount of loans we originated since 2014, increased from 5.4% as of December 31, 2019 to 5.6% as of September 30, 2020.

Business Outlook

The extent to which the COVID-19 pandemic impacts the Company’s results of operations will depend on future developments of the pandemic in China and across the globe, which are subject to changes and substantial uncertainty and therefore cannot be predicted. For the fourth quarter of 2020, based on the information available as of the date of this press release, we expect net income to be between RMB50 million and RMB100 million.

The above outlook is based on the current market conditions and reflects our current and preliminary estimates of market and operating conditions, which are all subject to substantial uncertainty.

Conference Call

CNFinance’s management will host an earnings conference call at 8:00 PM U.S. Eastern Time on Monday, November 23, 2020 (9:00 AM Beijing/ Hong Kong Time on Tuesday, November 24, 2020).

Dial-in numbers for the live conference call are as follows:

International:

+1-412-902-4272

Mainland China

+86-4001-201203

United States:

+1-888-346-8982

Hong Kong:

+852-3018-4992

Passcode:

CNFinance

A telephone replay of the call will be available after the conclusion of the conference call until 11:59 PM ET on December 1, 2020.

Dial-in numbers for the replay are as follows:

International:

+1-412-317-0088

United States:

+1-877-344-7529

Passcode:

10149970

A live and archived webcast of the conference call will be available on the Investor Relations section of CNFinance’s website at http://ir.cashchina.cn/.

Statement Regarding Preliminary Unaudited Financial Information

The unaudited financial information set out in this earnings release is preliminary and subject to potential adjustments. Adjustments to the consolidated financial statements may be identified when audit work has been performed for the Company’s year-end audit, which could result in significant differences from this preliminary unaudited financial information.

Exchange Rate

The Company’s business is primarily conducted in China and all of the revenues are denominated in Renminbi (“RMB”). This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars are made at a rate of RMB6.8101 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Board of Governors of the Federal Reserve System as of September 30, 2020. No representation is made that the RMB amounts could have been, or could be, converted, realized or settled into U.S. dollars at that rate on September 30, 2020, or at any other rate.

Safe Harbor Statement

This press release contains forward-looking statements made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will”, “expects”, “anticipates”, “future”, “intends”, “plans”, “believes”, “estimates”, “confident” and similar statements. The Company may also make written or oral forward-looking statements in its reports filed with or furnished to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Any statements that are not historical facts, including statements about the Company’s beliefs and expectations, are forward-looking statements that involve factors, risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors and risks include, but not limited to the following: its goals and strategies, its ability to achieve and maintain profitability, its ability to retain existing borrowers and attract new borrowers, its ability to maintain and enhance the relationship and business collaboration with its trust company partners and to secure sufficient funding from them, the effectiveness of its risk assessment process and risk management system, its ability to maintain low delinquency ratios for loans it originated, and relevant government policies and regulations relating to the Company’s corporate structure, business and industry. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is current as of the date of the press release, and the Company does not undertake any obligation to update such information, except as required under applicable law.

About CNFinance Holdings Limited

CNFinance Holdings Limited (NYSE: CNF) (“CNFinance” or the “Company”) is a leading home equity loan service provider in China. CNFinance facilitates loans by connecting micro- and small-enterprise (“MSE”) owners with its funding partners. The Company’s primary target borrower segment is MSE owners who own real properties in Tier 1 and Tier 2 cities in China. The loans CNFinance facilitated are primarily funded through a trust lending model with its trust company partners who are well-established with sufficient funding sources and have licenses to engage in lending business nationwide. The Company’s risk mitigation mechanism is embedded in the design of its loan products, supported by an integrated online and offline process focusing on risks of both borrowers and collateral and further enhanced by effective post-loan management procedures. 

CNFINANCE HOLDINGS LIMITED

Unaudited condensed consolidated balance sheets

(In thousands)


December 31,


         


2019          

 


September 30,


                  2020                   


RMB


RMB


US$


Assets

Cash and cash equivalents

1,705,356

1,686,714

247,678

Loans principal, interest and financing     service fee receivables (net of allowance of RMB1,108,078 and RMB1,722,554 as of Dec 31, 2019 and September  30, 2020, respectively)

10,258,019

8,738,182

 

 

 

1,283,121

Investment securities

654,328

668,128

98,108

Property and equipment

9,196

5,057

743

Intangible assets and goodwill

3,738

3,367

494

Deferred tax assets

16,441

23,948

3,517

Deposits

133,513

115,398

16,945

Right-of-use assets

38,134

23,206

3,408

Other assets

207,524

645,000

94,712


Total assets


13,026,249


11,909,000


1,748,726


Liabilities and shareholders’ equity

Interest-bearing borrowings

    Borrowings under agreements to repurchase 

870,778

758,857

111,431

    Other borrowings

6,652,138

5,304,790

778,959

Accrued employee benefits

37,276

24,959

3,665

Income tax payable

136,932

324,035

47,582

Deferred tax liabilities

359,286

166,505

24,450

Lease liabilities

38,134

23,141

3,398

Credit risk mitigation position

928,702

1,161,911

170,616

Other liabilities

404,469

511,776

75,149


Total liabilities


9,427,715


8,275,974


1,215,250

—————–

—————–

—————–

Ordinary shares(3,800,000,000 shares authorized; 1,371,643,240 shares with USD0.0001 as par value issued as of December 31, 2019 and  September  30, 2020)

917

917

135

Additional paid-in capital

937,590

984,145

144,512

Retained earnings

2,662,146

2,653,847

389,693

Accumulated other comprehensive losses

(2,119)

(5,883)

(864)


Total shareholders’ equity


3,598,534


3,633,026


533,476


—————–


—————–


—————–


Total liabilities and shareholders’ equity


13,026,249


11,909,000


1,748,726

 

CNFINANCE HOLDINGS LIMITED

Unaudited condensed consolidated statements of comprehensive income

(In thousands, except for earnings per share and earnings per ADS)


Three months ended September 30,


2019


2020


2020


RMB


RMB


US
$


Interest and fees income

Interest and financing service fee on loans

675,479

472,464

69,377

Interest on deposits with banks

3,450

3,495

513


Total interest and fees income


678,929


475,959


69,890


Interest and fees expenses


(294,776)


(184,349)


(27,070)


Net interest and fees income


384,153


291,610


42,820

Collaboration cost for sales partners

(57,416)

(112,480)

(16,517)


Net interest and fees income after
co
llaboration cost


326,737


179,130


26,303

Provision for credit losses

(54,863)

(31,088)

(4,565)


Net interest and fees income after collaboration cost and provision for credit losses


271,874


148,042


21,738

Realized gains on sales of investments, net

18,250

7,232

1,062

Other gains, net

61,800

37,364

5,487


Total non-interest revenue


80,050


44,596


6,549


Operating expenses

Employee compensation and benefits

(52,994)

(46,687)

(6,856)

Share-based compensation expenses

(3,972)

(15,518)

(2,279)

Taxes and surcharges

(11,771)

(11,900)

(1,747)

Operating lease cost

(8,700)

(4,362)

(641)

Other expenses

(35,194)

(39,375)

(5,782)


Total operating expenses


(112,631)


(117,842)


(17,305)


Income before income tax


239,293


74,796


10,982

Income tax expense

(61,956)

(24,647)

(3,619)


Net income


177,337


50,149


7,363

Earnings per share

  Basic

0.13

0.04

0.006

  Diluted

0.12

0.03

0.004

Earnings per ADS (1 ADS equals 20 ordinary shares)

  Basic

2.59

0.73

0.107

  Diluted

2.35

0.67

0.098


Other comprehensive income

Net unrealized (losses)/gains on investment securities

(1,995)

75

11

Foreign currency translation adjustment

8,211

(8,482)

(1,246)


—————-


—————–


—————–


Comprehensive income


183,553


41,742


6,128

CNFINANCE HOLDINGS LIMITED

Unaudited condensed consolidated statements of comprehensive income

(In thousands, except for earnings per share and earnings per ADS)


Nine months ended September 30,


2019


2020


2020


RMB


RMB


US
$


Interest and fees income

Interest and financing service fee on loans

2,361,654

1,411,570

207,276

Interest on deposits with banks

11,606

12,142

1,783


Total interest and fees income


2,373,260


1,423,712


209,059


Interest and fees expenses


(1,073,027)


(572,003)


(83,993)


Net interest and fees income


1,300,233


851,709


125,066

Collaboration cost for sales partners

(98,265)

(310,723)

(45,627)


Net interest and fees income after
co
llaboration cost


1,201,968


540,986


79,439

Provision for credit losses

(322,925)

(308,460)

(45,294)


Net interest and fees income after collaboration cost and provision for credit losses


879,043


232,526


34,145

Realized gains on sales of investments, net

30,366

15,544

2,282

Other gains, net

95,344

117,828

17,302


Total non-interest revenue


125,710


133,372


19,584


Operating expenses

Employee compensation and benefits

(160,696)

(138,161)

(20,288)

Share-based compensation expenses

(11,915)

(46,554)

(6,836)

Taxes and surcharges

(47,699)

(36,784)

(5,401)

Operating lease cost

(28,572)

(17,164)

(2,520)

Other expenses

(118,955)

(93,986)

(13,801)


Total operating expenses


(367,837)


(332,649)


(48,846)


Income before income tax


636,916


33,249


4,883

Income tax expense

(163,255)

(23,677)

(3,477)


Net income


473,661


9,572


1,406

Earnings per share

  Basic

0.35

0.01

0.001

  Diluted

0.31

0.01

0.001

Earnings per ADS (1 ADS equals 20 ordinary shares)

  Basic

6.91

0.14

0.021

  Diluted

6.27

0.13

0.019


Other comprehensive income

Net unrealized (losses)/gains on investment securities

(1,128)

422

62

Foreign currency translation adjustment

8,011

(4,184)

(614)


—————-


—————–


—————–


Comprehensive income


480,544


5,810


854


[1] Refers to the total amount of loans CNFinance originated during the relevant period.

2 Refers to the total amount of loans outstanding for CNFinance at the end of the relevant period.

Cision View original content:http://www.prnewswire.com/news-releases/cnfinance-announces-third-quarter-of-2020-unaudited-financial-results-301179031.html

SOURCE CNFinance Holdings Limited

Anaplan Announces Appointment of Brooke Major-Reid to its Board of Directors

Anaplan Announces Appointment of Brooke Major-Reid to its Board of Directors

SAN FRANCISCO–(BUSINESS WIRE)–Anaplan, Inc. (NYSE: PLAN), provider of a cloud-native platform for orchestrating business performance today announced the appointment of Brooke Major-Reid to its Board of Directors effective November 20, 2020.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123006231/en/

Brooke Major-Reid (Photo: Business Wire)

Brooke Major-Reid (Photo: Business Wire)

Brooke Major-Reid is Corporate Treasurer of Macy’s, Inc., the omnichannel retailer. She is a seasoned, entrepreneurial finance and strategy executive who also successfully led short-term credit products businesses, among other senior roles, at Morgan Stanley. Before joining Macy’s in 2019, Ms. Major-Reid was the SVP, Head of Strategy, at Cross River – a FinTech Bank – from 2017 to 2019. She founded BEAMR Group Inc. in 2015, providing strategic and financial advice to startups, with a focus on woman- and minority-founded enterprises. Ms. Major-Reid also serves as a board member for Uncommon Schools, a nonprofit charter school management organization.

Ms. Major-Reid has an extensive finance background, including 15+ years of experience in structured finance origination, short-term credit product marketing, and analytics, institutional capital raising, and business development. She has a proven track record of demonstrating exceptional leadership, optimizing client relationships, and identifying untapped business opportunities in under-penetrated and high-potential market segments. Ms. Major-Reid holds an MBA from Harvard Business School and a BBA in International Business with a concentration in Finance from Howard University.

“This is an exciting time for us as we welcome Brooke to our Board,” said Frank Calderoni, Chairman and CEO, Anaplan. “Brooke’s deep expertise in finance and her boundless passion for diversity, equity, and inclusion will help us as we continue to grow and mature as a company. We have an ambitious agenda for Anaplan’s future, and her experience will be incredibly valuable. She is an accomplished business leader, and I’m looking forward to working with her.”

“Anaplan is on the leading edge of innovation in the mission-critical area of Corporate Planning. I firmly believe that Anaplan’s ongoing success will not only be an operational game-changer for companies across the globe, but will also support optimization of strategic choices, creating tremendous value for all stakeholders,” said Brooke Major-Reid. “It is a privilege to join this esteemed Board in partnership with a pioneering management team shaping the future of this dynamic space.”

About Anaplan

Anaplan, Inc. (NYSE: PLAN) is a cloud-native enterprise SaaS company helping global enterprises orchestrate business performance. Leaders across industries rely on our platform – powered by our proprietary Hyperblock® technology – to connect teams, systems, and insights from across their organizations to continuously adapt to change, transform how they operate, and reinvent value creation. Based in San Francisco, Anaplan has over 20 offices globally, 175 partners, and approximately 1,500 customers worldwide. To learn more, visit anaplan.com.

Anthony Harrison

[email protected]

415-794-9339

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Networks Internet Data Management Technology Software

MEDIA:

Photo
Photo
Brooke Major-Reid (Photo: Business Wire)

Atlanticus Holdings Corporation announces appointment of Senior Vice Presidents of Marketing and Business Development

ATLANTA, Nov. 23, 2020 (GLOBE NEWSWIRE) —  Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “we,” “our” or “us”), a technology-enabled  financial services company, today announced the appointments of Matt Zalubowski as Senior Vice President of Marketing and Kurt Brown as Senior Vice President, Business Development.

Matt Zalubowski will lead all product marketing programs as Atlanticus continues to facilitate financial solutions to meet the needs of everyday consumers. Prior to this role, Matt was responsible for leading Atlanticus’ retail credit business development efforts.

“We are a leader in leveraging technology to enable our bank partners to bring financial solutions to over 90 million consumers who are underserved by big banks. As our platform growth continues across multiple asset classes, product offerings, marketing channels, and partnerships, I am excited to have someone with Matt’s experience lead our marketing efforts,” said Jeff Howard, President, Atlanticus Holdings Corporation.

Matt Zalubowski added, “I am looking forward to leveraging my consumer finance experience to help tell our story and accelerate our growth. Atlanticus’ service offerings help address the needs of those that are financially underserved, and I am excited to help the organization further this pursuit.”

Kurt Brown will lead business development across traditional and emerging industry verticals including general and specialty retail, e-commerce, furniture, automotive, consumer electronics, elective healthcare and home improvement.

Kurt comes to Atlanticus after spending 16 years in client partnerships and new business development with Alliance Data Card Services. In that time, Kurt led the client facing new business development team responsible for new co-branded and private label credit programs.

“We are excited to have Kurt lead our business development efforts. Kurt’s depth and broad range of expertise in financial services are a significant addition to both our leadership team and our technology platform’s Fortiva® and Aspire® branded private label, installment, and general-purpose card services.  His contributions will further enhance our industry-leading technology and partner-centric credit platforms,” said David Caruso, Chief Commercial Officer, Atlanticus Holdings Corporation.

“I am excited to join the talented team at Atlanticus and lead the growth efforts of the Fortiva Retail Credit brand to help grow their strong family of partnerships.  Atlanticus has a proven, market leading technology suite and customer servicing platform which makes it easy for retail partners to drive sales and deliver buying power and satisfaction across their customer base,” said Kurt Brown.

About Atlanticus Holdings Corporation

Founded in 1996, our business  utilizes proprietary analytics and a flexible technology platform to enable financial institutions to provide various credit and related financial services and products to the financially underserved consumer credit market. We apply the experience gained and infrastructure built from servicing over 17 million customers and $25 billion in consumer loans over our 24-year operating history to support lenders that originate a range of consumer loan products. These products include retail credit and general-purpose credit cards marketed through our omnichannel platform, including retail point-of-sale, direct mail solicitation, Internet-based marketing, and partnerships with third parties. Additionally, through its CAR subsidiary, Atlanticus serves the individual needs of automotive dealers and automotive non-prime financial organizations with multiple financing and service programs.



Contact:
Investor Relations 
Mitch Saunders 
770.828.2000
[email protected]

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results

– Conference Call and Webcast Today, November 23 at 4:30 p.m. EST

PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal year ended September 30, 2020. The company is hosting a conference call at 4:30 p.m. EST to discuss results.

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company’s website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 8492751.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 8492751.

Selected Recent Events

  • Earned a $20 million milestone payment from Amgen following the administration of the first dose of AMG 890, now called olpasiran, in a Phase 2 clinical study
  • Hosted a key opinion leader webinar on ARO-ENaC, the company’s investigational RNAi therapeutic being developed as a treatment for patients with cystic fibrosis
  • Initiated a Phase 1b study of ARO-HIF2, the company’s first tumor targeted investigational RNAi therapeutic being developed as a treatment for patients with clear cell renal cell carcinoma
  • Presented new clinical data from Phase 1/2 studies of both wholly owned cardiometabolic candidates, ARO-APOC3 and ARO-ANG3, at multiple medical meetings, including the European Society of Cardiology and the American Heart Association meetings, and subsequently hosted key opinion leader webinars to discuss the data and plans for future development of the product candidates
  • Presented new clinical data at The Liver Meeting Digital Experience, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD) on ARO-AAT, Arrowhead’s candidate against liver disease associated with alpha-1 antitrypsin deficiency, showing that ARO-AAT strongly reduced the production of mutant Z-AAT protein and led to improvements in multiple biomarkers of alpha-1 liver disease
  • Signed an agreement with Takeda to co-develop and co-commercialize ARO-AAT, which includes $300 million upfront, $740 million in potential milestone payments, a 50/50 profit sharing agreement in the U.S., and 20-25% royalty on sales outside the U.S.

Selected Fiscal Year 2020 Financial Results

ARROWHEAD PHARMACEUTICALS, INC.

CONSOLIDATED CONDENSED FINANCIAL INFORMATION

 

 

 

 

 

 

 

 

Year Ended September 30,

 

OPERATING SUMMARY

2020

 

2019

 

 

 

 

 

 

 

 

REVENUE

$

87,992,066

 

 

$

168,795,577

 

OPERATING EXPENSES

 

 

 

 

 

 

Research and development

 

128,874,979

 

 

 

81,048,686

 

General and administrative expenses

 

52,275,890

 

 

 

26,556,257

 

TOTAL OPERATING EXPENSES

 

181,150,869

 

 

 

107,604,943

 

OPERATING INCOME (LOSS)

 

(93,158,803

)

 

 

61,190,634

 

OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES

 

8,605,577

 

 

 

6,784,215

 

NET INCOME (LOSS)

$

(84,553,226

)

 

$

67,974,849

 

 

 

 

 

 

 

 

NET INCOME (LOSS) PER SHARE (DILUTED)

$

(0.84

)

 

$

0.69

 

WEIGHTED AVERAGE SHARES OUTSTANDING (DILUTED)

 

100,722,224

 

 

 

98,607,815

 

 

 

 

 

 

 

 

FINANCIAL POSITION SUMMARY

September 30,

 

September 30,

 

 

2020

 

2019

 

CASH AND CASH EQUIVALENTS

$

143,582,667

 

 

$

221,804,128

 

SHORT-TERM INVESTMENTS AND MARKETABLE SECURITIES

 

171,909,470

 

 

 

36,899,894

 

LONG-TERM INVESTMENTS

 

137,486,883

 

 

 

44,175,993

 

TOTAL CASH RESOURCES (CASH AND INVESTMENTS)

 

452,979,020

 

 

 

302,880,015

 

OTHER ASSETS

 

69,524,723

 

 

 

46,965,422

 

TOTAL ASSETS

 

522,503,743

 

 

 

349,845,437

 

TOTAL CURRENT DEFERRED REVENUE

 

19,291,075

 

 

 

77,769,629

 

TOTAL LONG TERM DEFERRED REVENUE

 

 

 

 

5,035,142

 

OTHER LIABILITIES

 

41,433,536

 

 

 

23,004,414

 

TOTAL LIABILITIES

 

60,724,611

 

 

 

105,809,185

 

TOTAL STOCKHOLDERS’ EQUITY

 

461,779,132

 

 

 

244,036,252

 

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

522,503,743

 

 

$

349,845,437

 

 

 

 

 

 

 

 

SHARES OUTSTANDING

 

102,376,303

 

 

 

95,506,271

 

 

 

 

 

 

 

 

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company’s email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

Vince Anzalone, CFA

626-304-3400

[email protected]

Investors:

LifeSci Advisors, LLC

Brian Ritchie

212-915-2578

[email protected]

www.lifesciadvisors.com

Media:

LifeSci Communications, LLC

Josephine Belluardo, Ph.D.

646-751-4361

[email protected]

www.lifescicommunications.com

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Pharmaceutical Health Oncology Clinical Trials

MEDIA:

Logo
Logo